Omega-3 fatty acids for depression in multiple sclerosis

A randomized pilot study

Lynne Shinto, Gail Marracci, David C. Mohr, Lauren Bumgarner, Charles Murchison, Angela Senders, Dennis Bourdette

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Multiple sclerosis is the most common chronic disabling disease in the central nervous system in young to middle aged adults. Depression is common in multiple sclerosis (MS) affecting between 50-60% of patients. Pilot studies in unipolar depression report an improvement in depression when omega-3 fatty acids are given with antidepressants. The objective of this study was to investigate whether omega-3 fatty acid supplementation, as an augmentation therapy, improves treatment-resistant major depressive disorder (MDD) in people with MS. We performed a randomized, double-blind, placebo-controlled pilot study of omega-3 fatty acids at six grams per day over three months. The primary outcome was a 50% or greater improvement on the Montgomery-Asberg Depression Rating Scale (MADRS). Thirty-nine participants were randomized and thirty-one completed the 3-month intervention. Improvement on MADRS between groups was not significantly different at the 3-month end point with 47.4%in the omega-3 fatty acid group and 45.5%in the placebo group showing 50% or greater improvement (p = 0.30). Omega-3 fatty acids as an augmentation therapy for treatment-resistant depression in MS was not significantly different than placebo in this pilot trial. Omega-3 fatty acid supplementation at the dose given was well-tolerated over 3 months.

Original languageEnglish (US)
Article numbere0147195
JournalPLoS One
Volume11
Issue number1
DOIs
StatePublished - Jan 1 2016

Fingerprint

Omega-3 Fatty Acids
sclerosis
omega-3 fatty acids
Multiple Sclerosis
Depression
Treatment-Resistant Depressive Disorder
placebos
rating scales
Placebos
middle-aged adults
therapeutics
antidepressants
Major Depressive Disorder
Neurology
Depressive Disorder
chronic diseases
Antidepressive Agents
central nervous system
Chronic Disease
Central Nervous System

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Omega-3 fatty acids for depression in multiple sclerosis : A randomized pilot study. / Shinto, Lynne; Marracci, Gail; Mohr, David C.; Bumgarner, Lauren; Murchison, Charles; Senders, Angela; Bourdette, Dennis.

In: PLoS One, Vol. 11, No. 1, e0147195, 01.01.2016.

Research output: Contribution to journalArticle

Shinto, Lynne ; Marracci, Gail ; Mohr, David C. ; Bumgarner, Lauren ; Murchison, Charles ; Senders, Angela ; Bourdette, Dennis. / Omega-3 fatty acids for depression in multiple sclerosis : A randomized pilot study. In: PLoS One. 2016 ; Vol. 11, No. 1.
@article{981d5521e69b4fc99270499a39bc6c98,
title = "Omega-3 fatty acids for depression in multiple sclerosis: A randomized pilot study",
abstract = "Multiple sclerosis is the most common chronic disabling disease in the central nervous system in young to middle aged adults. Depression is common in multiple sclerosis (MS) affecting between 50-60{\%} of patients. Pilot studies in unipolar depression report an improvement in depression when omega-3 fatty acids are given with antidepressants. The objective of this study was to investigate whether omega-3 fatty acid supplementation, as an augmentation therapy, improves treatment-resistant major depressive disorder (MDD) in people with MS. We performed a randomized, double-blind, placebo-controlled pilot study of omega-3 fatty acids at six grams per day over three months. The primary outcome was a 50{\%} or greater improvement on the Montgomery-Asberg Depression Rating Scale (MADRS). Thirty-nine participants were randomized and thirty-one completed the 3-month intervention. Improvement on MADRS between groups was not significantly different at the 3-month end point with 47.4{\%}in the omega-3 fatty acid group and 45.5{\%}in the placebo group showing 50{\%} or greater improvement (p = 0.30). Omega-3 fatty acids as an augmentation therapy for treatment-resistant depression in MS was not significantly different than placebo in this pilot trial. Omega-3 fatty acid supplementation at the dose given was well-tolerated over 3 months.",
author = "Lynne Shinto and Gail Marracci and Mohr, {David C.} and Lauren Bumgarner and Charles Murchison and Angela Senders and Dennis Bourdette",
year = "2016",
month = "1",
day = "1",
doi = "10.1371/journal.pone.0147195",
language = "English (US)",
volume = "11",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "1",

}

TY - JOUR

T1 - Omega-3 fatty acids for depression in multiple sclerosis

T2 - A randomized pilot study

AU - Shinto, Lynne

AU - Marracci, Gail

AU - Mohr, David C.

AU - Bumgarner, Lauren

AU - Murchison, Charles

AU - Senders, Angela

AU - Bourdette, Dennis

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Multiple sclerosis is the most common chronic disabling disease in the central nervous system in young to middle aged adults. Depression is common in multiple sclerosis (MS) affecting between 50-60% of patients. Pilot studies in unipolar depression report an improvement in depression when omega-3 fatty acids are given with antidepressants. The objective of this study was to investigate whether omega-3 fatty acid supplementation, as an augmentation therapy, improves treatment-resistant major depressive disorder (MDD) in people with MS. We performed a randomized, double-blind, placebo-controlled pilot study of omega-3 fatty acids at six grams per day over three months. The primary outcome was a 50% or greater improvement on the Montgomery-Asberg Depression Rating Scale (MADRS). Thirty-nine participants were randomized and thirty-one completed the 3-month intervention. Improvement on MADRS between groups was not significantly different at the 3-month end point with 47.4%in the omega-3 fatty acid group and 45.5%in the placebo group showing 50% or greater improvement (p = 0.30). Omega-3 fatty acids as an augmentation therapy for treatment-resistant depression in MS was not significantly different than placebo in this pilot trial. Omega-3 fatty acid supplementation at the dose given was well-tolerated over 3 months.

AB - Multiple sclerosis is the most common chronic disabling disease in the central nervous system in young to middle aged adults. Depression is common in multiple sclerosis (MS) affecting between 50-60% of patients. Pilot studies in unipolar depression report an improvement in depression when omega-3 fatty acids are given with antidepressants. The objective of this study was to investigate whether omega-3 fatty acid supplementation, as an augmentation therapy, improves treatment-resistant major depressive disorder (MDD) in people with MS. We performed a randomized, double-blind, placebo-controlled pilot study of omega-3 fatty acids at six grams per day over three months. The primary outcome was a 50% or greater improvement on the Montgomery-Asberg Depression Rating Scale (MADRS). Thirty-nine participants were randomized and thirty-one completed the 3-month intervention. Improvement on MADRS between groups was not significantly different at the 3-month end point with 47.4%in the omega-3 fatty acid group and 45.5%in the placebo group showing 50% or greater improvement (p = 0.30). Omega-3 fatty acids as an augmentation therapy for treatment-resistant depression in MS was not significantly different than placebo in this pilot trial. Omega-3 fatty acid supplementation at the dose given was well-tolerated over 3 months.

UR - http://www.scopus.com/inward/record.url?scp=84958214303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958214303&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0147195

DO - 10.1371/journal.pone.0147195

M3 - Article

VL - 11

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 1

M1 - e0147195

ER -